ASCLETIS-B (01672) surged over 7% again, up 6.8% to HK$11.62 at press time with turnover reaching HK$56.46 million. On the news front, Ascletis announced that its board of directors has decided to exercise the repurchase mandate and will conduct share repurchases in the open market from time to time based on market conditions, using up to HK$300 million for the proposed share buyback program.

Securities analysts previously noted that the company has multiple catalysts in the second half, with several important clinical data readouts imminent. Based on clinical trial progress and company announcements, they expect that Q4 2025 will see topline data from ASC30 oral Phase II, ASC47 Phase I, and ASC50 Phase I trials, while Q1 2026 will see topline data from ASC30 subcutaneous injection Phase II trial. Additionally, the company expects to submit 2-3 new pipeline INDs to the FDA within the next 6-9 months, including a dual-target peptide weight management pipeline.